Business Context and Reporting Period
This Form 8-K filing by PUMA BIOTECHNOLOGY, INC. (PBYI) reports a corporate governance event dated December 15, 2016. The Company is a Delaware corporation headquartered in Los Angeles, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing transfer and does not contain financial statement data.
Material Changes
The primary material change is the voluntary transfer of the listing of the Company's Common Stock from The New York Stock Exchange (NYSE) to The NASDAQ Stock Market (NASDAQ).
- Authorization Date: December 15, 2016 (Board of Directors).
- Notice to NYSE: December 19, 2016.
- Expected NYSE Delisting: Close of trading on December 30, 2016.
- Expected NASDAQ Commencement: January 3, 2017.
- Stock Symbol: Will remain "PBYI".
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial outlook, guidance, risks, contingencies, or unusual items. The document serves solely to notify the market of the exchange transfer.
Investor Verification Checklist
- Confirm the cessation of trading on the NYSE on December 30, 2016.
- Verify the commencement of trading on NASDAQ on January 3, 2017.
- Ensure the stock symbol remains "PBYI" across the exchange transition.
- Review the attached press release (Exhibit 99.1) for additional details on the rationale for the transfer.